Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors
Odylia Therapeutics is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors....
Odylia Therapeutics Announces Partnership with PURA Syndrome Foundation
Atlanta, GA -- December 17, 2024 Odylia Therapeutics is excited to announce a new partnership with the PURA Syndrome Foundation (PSF), a nonprofit whose mission is to support and drive research, raise awareness in the general community, as well as connect, educate, serve, and empower families...
Odylia Therapeutics Welcomes Elizabeth Attias to Board of Directors
Odylia Therapeutics is excited to announce the appointment of Elizabeth Attias to its Board of Directors....
Odylia Therapeutics Announces Partnership with Smith Kingsmore Syndrome Foundation
Smith Kingsmore Syndrome Foundation (SKSF), a nonprofit whose mission is to improve the lives of all people impacted by Smith-Kingsmore syndrome by accelerating research and connecting our global community. ...
Odylia Therapeutics Receives Translational Research Award from Foundation Fighting Blindness to Accelerate Development of Gene Therapy for RPGRIP1
Atlanta, GA, May 20, 2024 — Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1...
Odylia Therapeutics Announces Promotion of Ashley Winslow, Ph.D., to CEO
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia Therapeutics Announces Appointment of Khandan Baradaran, Ph.D. to Board of Directors
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....